News

AZD1446 is a selective modulator of the alpha4beta2 neuronal nicotinic receptor that arose out of a research collaboration conducted by Targacept and AstraZeneca. As per the research and

Bristol-Myers Squibb is said to benefit from BT by deriving greater value from its network services through increased standardization and innovation. The contract extension covers all Bristol-Myers Squibb

McKesson Strategic Supply Sourcing is believed to give providers enhanced visibility and control over their medical-surgical supply spending. The solution also has the ability to support multiple materials

The grant has been provided as part of the ‘5050 Plan’ that aims to incentivize and assist start-up, technology-based companies within HHTZ, Hangzhou, Zhejiang Province. HHTZ director Sheng

The KDM-1102 drug is a new sublingual formulation of propanolol whose formulation development is now completed and can be produced in large volume. The sublingual formulation is designed

According to the company, the Phase III trial will be a randomized, prospective, multi-site, double-blind, placebo-controlled, parallel-group study of C-Topical Solution as an anesthetic prior to a diagnostic

As per the extended contract, the company will develop a controlled release formulation that combines the client’s optimized product candidate with their proprietary drug delivery technology, PolyActive. If

As per the agreement, Ipsen is granted two exclusive options to exclusively license Oncodesign’s LRRK2 inhibitor program with worldwide development, manufacturing and commercialization rights. Oncodesign will receive milestone

The company claims Isis’ ISIS-SMNRx is developed to compensate for the underlying genetic defect that causes SMA. As per the collaboration, Isis will receive an upfront payment of